{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-151893","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2026-04-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.718443+00:00","generated_at":"2026-05-15T06:35:43.580826+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"IDEAYA announces Phase 2/3 trial met primary endpoint; darovasertib combo reduces progression risk by 58%","bullets":["Darovasertib + crizotinib reduced risk of disease progression by 58% (HR 0.42, p<0.0001) in 1L HLA-A*02:01-negative mUM.","Median PFS 6.9 months vs 3.1 months for investigator choice therapy (ICT) arm.","ORR 37.1% vs 5.8% for ICT; 5 complete responses in combo arm, none in ICT.","NDA submission to FDA targeted for second half of 2026.","Safety profile manageable; Grade 3+ events included diarrhea, syncope, hypotension."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-151893","json":"https://secwatch.observer/filing/0001193125-26-151893.json","markdown":"https://secwatch.observer/filing/0001193125-26-151893.md","text":"https://secwatch.observer/filing/0001193125-26-151893.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526151893/0001193125-26-151893-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526151893/d114952d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:35:43.580826+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}